Bristol-Myers Squibb has announced its new-look leadership after the Celgene takeover goes through, and it reveals a mixed bag of new hires, sideways moves, and departures.
Celgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use alongside Roche’s Rituxan for two additional forms of indolent non-Hodgkin
Celgene and Acceleron Pharma have submitted their blood disorder drug luspatercept for approval with the FDA, setting up what could be a new blockbuster for the soon-to-be acquired Celgene.
Bristol-Myers Squibb’s mega-merger with Celgene looks set to go ahead after activist hedge fund Starboard Value backed out of a campaign against the $74 billion deal.
Celgene has filed its highly anticipated oral MS drug ozanimod with the US regulator, more than a year after the FDA rejected it because of a bureaucratic foul-up.